Development of minimally invasive diagnostic methods and epigenomic therapies focusing on founder epi-drivers in lung adenocarcinoma.
Project/Area Number |
18H02894
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Review Section |
Basic Section 55040:Respiratory surgery-related
|
Research Institution | Aichi Cancer Center Research Institute |
Principal Investigator |
Imoto Issei 愛知県がんセンター(研究所), 研究所長, 研究所長 (30258610)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2021)
|
Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2019: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
Keywords | 肺腺癌 / エピゲノム / ドライバー / リキッドバイオプシー / 治療標的 |
Outline of Final Research Achievements |
Although various driver mutations have been identified and molecular targeted therapies are being developed in lung adenocarcinoma (LAD), many cases lack these driver mutations and drug-resistance is easily acquired based on the temporal and spatial heterogeneity of cancers. In this study, we focused on the founder epi-driver type tumor suppressor genes (TSGs), which shows frequent tumor-specific hypermethylation from early stage, as a diagnostic and therapeutic target molecule that can overcome these issues. As a result, we have developed epi-markers that can be detected in plasma to detect early stage LAC or recurrence and predict therapeutic efficacy. We also identified therapeutic target epi-driver TSGs and related molecular pathways, and selected chemical compounds that mimic the activation of these pathways by through in silico screening.
|
Academic Significance and Societal Importance of the Research Achievements |
がん領域では、遺伝子パネル検査やエクソーム、全ゲノム解析の結果から、腫瘍の網羅的な解析による癌細胞特異的治療標的検出や血漿を使った早期、再発、治療効果診断に有用な遺伝子変異の同定が進んでいる。特にリキッドバイオプシーは低侵襲で繰り返し行える検査法として臨床実装されており、腫瘍組織のゲノム情報が不要な各癌種に固有のバイオマーカーの同定は、早期のスクリーニング検査や組織のない症例での治療効果の評価、原発不明がんの原発巣予測などに応用可能な重要課題である。本課題の成果は、肺腺癌の早期診断マーカーとその検出法の開発に有用な情報を提供するもので、臨床応用が見込める点で意義がある。
|
Report
(4 results)
Research Products
(51 results)
-
-
[Journal Article] Functionally confirmed compound heterozygous ADAM17 missense loss-of-function variants cause neonatal inflammatory skin and bowel disease 12021
Author(s)
Imoto I, Saito M, Suga K, Kohmoto T, Otsu M, Horiuchi K, Nakayama H, Higashiyama S, Sugimoto M, Sasaki A, Homma Y, Shono M, Nakagawa R, Hayabuchi Y, Tange S, Kagami S, Masuda K
-
Journal Title
Scientific reports
Volume: 11
Issue: 1
Pages: 9552-9552
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
[Journal Article] Establishment and Characterization of a New Malignant Peritoneal Mesothelioma Cell Line, KOG-1, From the Ascitic Fluid of a Patient With Pemetrexed Chemotherapy Resistance2020
Author(s)
Akahane Tomoko, Hirasawa Akira, Imoto Issei, Okubo Aki, Itoh Manabu, Nanki Yoshiko, Yoshihama Tomoko, Tominaga Eichiro, Aoki Daisuke.
-
Journal Title
Hum Cell
Volume: 33
Issue: 1
Pages: 272-282
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
[Journal Article] Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases2020
Author(s)
Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Yamaji T, et al
-
Journal Title
Nature Genetics
Volume: 52
Issue: 7
Pages: 669-679
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer2020
Author(s)
Lin Y, Nakatochi M, Hosono Y, Ito H, Kamatani Y, Inoko A, Sakamoto H, Kinoshita F, Kobayashi Y, Ishii H, Yamaji T,et al.
-
Journal Title
Nature Communications
Volume: 11
Issue: 1
Pages: 3175-3175
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
[Journal Article] Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer2019
Author(s)
Ryoko Kikuchi-Koike, Kazunori Nagasaka, Hitoshi Tsuda, Yasuyuki Ishii, Masaru Sakamoto, Yoshihiro Kikuchi, Shiho Fukui, Yuko Miyagawa, Haruko Hiraike, Takayuki Kobayashi, Takayuki Kinoshita, Yae Kanai, Tatsuhiro Shibata, Issei Imoto, Johji Inazawa, Osamu Matsubara and Takuya Ayabe
-
Journal Title
BMC Cancer
Volume: 19
Issue: 1
Pages: 521-521
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
[Journal Article] Actin Cytoskeletal Reorganization Function of JRAB/MICAL-L2 Is Fine-tuned by Intramolecular Interaction between First LIM Zinc Finger and C-terminal Coiled-coil Domains.2019
Author(s)
Miyake K, Sakane A, Tsuchiya Y, Sagawa I, Tomida Y, Kasahara J, Imoto I, Watanabe S, Higo D, Mizuguchi K, Sasaki T.
-
Journal Title
Sci Rep.
Volume: 9
Issue: 1
Pages: 12794-12794
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Genome-wide association study to identify a new susceptibility locus for central serous chorioretinopathy in the Japanese population.2018
Author(s)
Miki A, Sakurada Y, Tanaka K, Semba K, Mitamura Y, Yuzawa M, Tajima A, Nakatochi M, Yamamoto K, Matsuo K, Imoto I, Honda S.
-
Journal Title
Invest Ophthalmol Vis Sci.
Volume: 59(13)
Issue: 13
Pages: 5542-5547
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Compound heterozygous missense variants in the ADAM17 gene cause neonatal inflammatory skin and bowel disease 1.2018
Author(s)
Imoto I, Saito M, Suga K, Naruto T, Kohmoto T, Otsu M, Horiuchi K, Nakayama H, Higashiyama S, Nakagawa R, Tange S, Masuda K, Kagami S.
Organizer
Annual meeting of American Society of Human Genetics 2018, SanDiego, USA
Related Report
Int'l Joint Research
-
-
-
-
-
-